Surgery Partners price target lowered to $35 from $40 at Benchmark

Benchmark analyst Bill Sutherland lowered the firm’s price target on Surgery Partners (SGRY) to $35 from $40 and keeps a Buy rating on the shares after the company reported in-line Q4 results and pointed to 2025 adjusted EBITDA to be up 10% at the midpoint, which the firm believes is “a conservative initial outlook.” However, based on its revised adjusted EBITDA outlook for 2025 being reduced in line with the midpoint of guidance, the firm reduced its price target the analyst noted.